N-[3-chloro-2-(1-oxidopyridin-1-ium-4-carbonyl)phenyl]-4-propan-2-yloxybenzenesulfonamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[3-chloro-2-(1-oxidopyridin-1-ium-4-carbonyl)phenyl]-4-propan-2-yloxybenzenesulfonamide
• 化学式: C21H19ClN2O5S
• 分子量: 446.9
• InChiKey: OVRMCLWWZGGLJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME USING SPECIFIC CCR9 RECEPTOR INHIBITORS/ANTAGONISTS<br/>[FR] PROCÉDÉ PROPHYLACTIQUE OU THÉRAPEUTIQUE DESTINÉ AU SYNDROME DE SJÖGREN UTILISANT DES INHIBITEURS/ANTAGONISTES SPÉCIFIQUES DU RÉCEPTEUR CCR9
  申请人：MILLENNIUM PHARM INC

  公开号：WO2014088113A1

  公开（公告）日：2014-06-12

  The present invention provides a prophylactic or therapeutic agent and a prophylactic or therapeutic method superior in the prophylaxis or treatment of Sjogren's syndrome. Provided are a prophylactic or therapeutic agent for Sjogren's syndrome, containing a compound represented by the formula (I): wherein each symbol is as defined in the Specification, or a pharmaceutically acceptable salt thereof, and a method for the prophylaxis or treatment of Sjogren's syndrome, including administering an effective amount of the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof.